Osteogenesis Imperfecta: A study of the patient journey in 13 European countries.
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
09 Sep 2024
09 Sep 2024
Historique:
received:
02
04
2024
accepted:
29
08
2024
medline:
10
9
2024
pubmed:
10
9
2024
entrez:
9
9
2024
Statut:
epublish
Résumé
Osteogenesis imperfecta (OI) is a heritable skeletal disorder and comprises various subtypes that differ in clinical presentation, with Type I considered the least severe and Types III/IV the most severe forms. The study aim was to understand the OI patient diagnostic and treatment journey across Europe. We conducted a qualitative, descriptive study to understand the OI patient journey. A selection of people with OI/their caregivers and clinicians involved in OI-patient care from across Europe were interviewed using a specially developed questionnaire. Between May 2022 and July 2022, 22 people with OI/caregivers and 22 clinicians (endocrinologists, orthopaedic surgeons, geneticists and metabolic specialists) from across Europe were interviewed. Our study showed various areas of concerns for the OI community. Timely diagnosis of OI is essential; misdiagnoses and a delay to treatment initiation are all too common. There are a lack of consensus guidelines regarding optimal treatments (including when bisphosphonate therapy should be initiated and the route of administration) and patient management throughout the duration of the patient's life. Adult OI patients do not have a medical home and are often managed by endocrinologists and rheumatologists. Adult care is often reactive based on the development of new symptoms. The psychosocial burden of OI impacts on the patient's quality of life. There is an urgent need for increased awareness about OI and its wide range of symptoms. In particular, there is a need for consensus guidelines outlining the optimum care throughout the duration of the OI patient's life.
Identifiants
pubmed: 39252130
doi: 10.1186/s13023-024-03345-0
pii: 10.1186/s13023-024-03345-0
doi:
Substances chimiques
Diphosphonates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
331Subventions
Organisme : Mereo BioPharma
ID : N/A
Informations de copyright
© 2024. The Author(s).
Références
Lim J, Grafe I, Alexander S, Lee B. Genetic causes and mechanisms of Osteogenesis Imperfecta. Bone. 2017;102:40–9.
doi: 10.1016/j.bone.2017.02.004
pubmed: 28232077
pmcid: 5607741
Unger S, Ferreira CR, Mortier GR, Ali H, Bertola DR, Calder A, et al. Nosology of genetic skeletal disorders: 2023 revision. Am J Med Genet A. 2023;191(5):1164–209.
doi: 10.1002/ajmg.a.63132
pubmed: 36779427
pmcid: 10081954
Yu H, Li C, Wu H, Xia W, Wang Y, Zhao J, Xu C. Pathogenic mechanisms of osteogenesis imperfecta, evidence for classification. Orphanet J Rare Dis. 2023;18(1):234.
doi: 10.1186/s13023-023-02849-5
pubmed: 37559063
pmcid: 10411007
Zhytnik L, Maasalu K, Reimann E, Prans E, Koks S, Martson A. Mutational analysis of COL1A1 and COL1A2 genes among Estonian osteogenesis imperfecta patients. Hum Genomics. 2017;11(1):19.
doi: 10.1186/s40246-017-0115-5
pubmed: 28810924
pmcid: 5558703
van Dijk FS, Byers PH, Dalgleish R, Malfait F, Maugeri A, Rohrbach M, et al. EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur J Hum Genet. 2012;20(1):11–9.
doi: 10.1038/ejhg.2011.141
pubmed: 21829228
Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101–16.
doi: 10.1136/jmg.16.2.101
pubmed: 458828
pmcid: 1012733
Marini JC, Dang Do AN. Osteogenesis Imperfecta. [Updated 2020 Jul 26]. Endotext [Internet]: South Dartmouth (MA): MDText.com, Inc.; 2000-. ; 2020. https://www.ncbi.nlm.nih.gov/books/NBK279109/
Lindahl K, Astrom E, Rubin CJ, Grigelioniene G, Malmgren B, Ljunggren O, Kindmark A. Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur J Hum Genet. 2015;23(8):1042–50.
doi: 10.1038/ejhg.2015.81
pubmed: 25944380
pmcid: 4795106
Van Dijk FS, Sillence DO. Osteogenesis Imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014;164A(6):1470–81.
doi: 10.1002/ajmg.a.36545
pubmed: 24715559
Basel D, Steiner RD. Osteogenesis Imperfecta: recent findings shed new light on this once well-understood condition. Genet Med. 2009;11(6):375–85.
doi: 10.1097/GIM.0b013e3181a1ff7b
pubmed: 19533842
Rauch F, Glorieux FH. Osteogenesis Imperfecta. Lancet. 2004;363(9418):1377–85.
doi: 10.1016/S0140-6736(04)16051-0
pubmed: 15110498
Commisssion E. Rare diseases: EU research on rare diseases [ https://research-and-innovation.ec.europa.eu/research-area/health/rare-diseases_en
Administration FaD. 2022 [ https://www.fda.gov/science-research/focus-areas-regulatory-science-report/cross-cutting-topics-rare-diseases-regulatory-science-research#:~:text=A%20rare%20disease%20is%20defined,recovery%20provisions%20of%20the%20act
Ralston SH, Gaston MS. Management of Osteogenesis Imperfecta. Front Endocrinol (Lausanne). 2019;10:924.
doi: 10.3389/fendo.2019.00924
pubmed: 32117044
Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, et al. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010;6:367–81.
pubmed: 20856683
pmcid: 2940745
Shi J, Ren M, Jia J, Tang M, Guo Y, Ni X, Shi T. Genotype-Phenotype Association Analysis Reveals New Pathogenic Factors for Osteogenesis Imperfecta Disease. Front Pharmacol. 2019;10:1200.
doi: 10.3389/fphar.2019.01200
pubmed: 31680973
pmcid: 6803541
Ren J, Xu X, Jian X, Wang J. Osteogenesis imperfecta type I: a case report. Exp Ther Med. 2014;7(6):1535–8.
doi: 10.3892/etm.2014.1653
pubmed: 24926339
pmcid: 4043568
Castro AR, Chougui K, Bilodeau C, Tsimicalis A. Exploring the views of Osteogenesis Imperfecta Caregivers on Internet-Based technologies: qualitative descriptive study. J Med Internet Res. 2019;21(12):e15924.
doi: 10.2196/15924
pubmed: 31850851
pmcid: 6939279
Rapoport M, Bober MB, Raggio C, Wekre LL, Rauch F, Westerheim I, et al. The patient clinical journey and socioeconomic impact of osteogenesis imperfecta: a systematic scoping review. Orphanet J Rare Dis. 2023;18(1):34.
doi: 10.1186/s13023-023-02627-3
pubmed: 36814274
pmcid: 9945474
Stoller JK. The challenge of Rare diseases. Chest. 2018;153(6):1309–14.
doi: 10.1016/j.chest.2017.12.018
pubmed: 29325986
Long JC, Best S, Nic Giolla Easpaig B, Hatem S, Fehlberg Z, Christodoulou J, Braithwaite J. Needs of people with rare diseases that can be supported by electronic resources: a scoping review. BMJ Open. 2022;12(9):e060394.
doi: 10.1136/bmjopen-2021-060394
pubmed: 36581982
pmcid: 9438091
Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet. 2013;14(10):681–91.
doi: 10.1038/nrg3555
pubmed: 23999272
Global Genes. RARE disease facts: Global Genes; 2023 [ https://globalgenes.org/learn/rare-disease-facts/
Ramalle-Gomara E, Dominguez-Garrido E, Gomez-Eguilaz M, Marzo-Sola ME, Ramon-Trapero JL, Gil-de-Gomez J. Education and information needs for physicians about rare diseases in Spain. Orphanet J Rare Dis. 2020;15(1):18.
doi: 10.1186/s13023-019-1285-0
pubmed: 31952528
pmcid: 6969468
Chazal PE, Aymé S. An Objective Approach to identify Priority Rare diseases for the development of solutions reducing the Diagnostic Delay based on French Data. Front Pharmacol. 2021;12:734601.
doi: 10.3389/fphar.2021.734601
pubmed: 34744718
pmcid: 8570372
Adachi T, El-Hattab AW, Jain R, Nogales Crespo KA, Quirland Lazo CI, Scarpa M et al. Enhancing Equitable Access to Rare Disease diagnosis and treatment around the World: a review of evidence, policies, and challenges. Int J Environ Res Public Health. 2023;20(6).
Thakur S. Advances in orphan drug development: time to change the status and stereotype. Perspect Clin Res. 2022;13(3):123–8.
doi: 10.4103/picr.picr_193_21
pubmed: 35928643
pmcid: 9345260
Gammie T, Lu CY, Babar ZU. Access to Orphan drugs: a Comprehensive Review of legislations, regulations and policies in 35 countries. PLoS ONE. 2015;10(10):e0140002.
doi: 10.1371/journal.pone.0140002
pubmed: 26451948
pmcid: 4599885
Long JC, Best S, Hatem S, Theodorou T, Catton T, Murray S, et al. The long and winding road: perspectives of people and parents of children with mitochondrial conditions negotiating management after diagnosis. Orphanet J Rare Dis. 2021;16(1):310.
doi: 10.1186/s13023-021-01939-6
pubmed: 34256797
pmcid: 8276535
Beauchemin M, Cohn E, Shelton RC. Implementation of clinical practice guidelines in the Health Care setting: a Concept Analysis. ANS Adv Nurs Sci. 2019;42(4):307–24.
doi: 10.1097/ANS.0000000000000263
pubmed: 30839334
pmcid: 6717691
Baldwin KD, Scherl SA. Orthopaedic aspects of child abuse. Instr Course Lect. 2013;62:399–403.
pubmed: 23395044
Altalib A, Althomali A, Alshahrani A, Alfrayyan A, Aljughaiman MS. Osteogenesis Imperfecta and child abuse from a forensic point of View. Cureus. 2021;13(1):e12790.
pubmed: 33628660
pmcid: 7891677
Dogba MJ, Bedos C, Durigova M, Montpetit K, Wong T, Glorieux FH, Rauch F. The impact of severe osteogenesis imperfecta on the lives of young patients and their parents - a qualitative analysis. BMC Pediatr. 2013;13:153.
doi: 10.1186/1471-2431-13-153
pubmed: 24074180
pmcid: 3852302
Botor M, Fus-Kujawa A, Uroczynska M, Stepien KL, Galicka A, Gawron K, Sieron AL. Osteogenesis Imperfecta: current and prospective therapies. Biomolecules. 2021;11(10).
Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10(10):CD005088.
pubmed: 27760454
Casado E, Gómez-Alonso C, Pintos-Morell G, Bou-Torrent R, Barreda-Bonis AC, Torregrosa JV, et al. Transition of patients with metabolic bone disease from paediatric to adult healthcare services: current situation and proposals for improvement. Orphanet J Rare Dis. 2023;18(1):245.
doi: 10.1186/s13023-023-02856-6
pubmed: 37644568
pmcid: 10463506
Genevaz D, Arnoux A, Marcel C, Brassier A, Pichard S, Feillet F, et al. Transition from child to adult health care for patients with lysosomal storage diseases in France: current status and priorities-the TENALYS study, a patient perspective survey. Orphanet J Rare Dis. 2022;17(1):68.
doi: 10.1186/s13023-022-02232-w
pubmed: 35189927
pmcid: 8862388
Grasemann C, Hoppner J, Burgard P, Schundeln MM, Matar N, Muller G, et al. Transition for adolescents with a rare disease: results of a nationwide German project. Orphanet J Rare Dis. 2023;18(1):93.
doi: 10.1186/s13023-023-02698-2
pubmed: 37098531
pmcid: 10131406
Patterson AM, O’Boyle M, VanNoy GE, Dies KA. Emerging roles and opportunities for rare disease patient advocacy groups. Ther Adv Rare Dis. 2023;4:26330040231164425.
doi: 10.1177/26330040231164425
pubmed: 37197559
pmcid: 10184204
Munoz Cortes R, Soriano Pastor JF, Monsalve Dolz V. Chronic pain in adults with osteogenesis imperfecta and its relationship to appraisal, coping, and quality of life: a cross-sectional study. Med (Baltim). 2022;101(40):e30256.
doi: 10.1097/MD.0000000000030256